Iodine-131 intervention in hyperthyroidism with hepatic insufficiency: Metabolomic evaluation.

Autor: Luo Z; Department of Nuclear Medicine, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang 330006, PR China., Lei Y; Department of Nuclear Medicine, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang 330006, PR China., Zeng L; Department of Nuclear Medicine, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang 330006, PR China., Chen X; Department of Nuclear Medicine, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang 330006, PR China., Liu S; Department of Nuclear Medicine, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang 330006, PR China., Zhang Q; Department of Nuclear Medicine, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang 330006, PR China. Electronic address: ndyfy01933@ncu.edu.cn.
Jazyk: angličtina
Zdroj: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2024 Apr; Vol. 173, pp. 116300. Date of Electronic Publication: 2024 Mar 01.
DOI: 10.1016/j.biopha.2024.116300
Abstrakt: Hyperthyroidism, often accompanied by hepatic insufficiency (HI), poses significant clinical challenges, highlighting the necessity for identifying optimal treatment strategies and early diagnostic biomarkers to improve patient outcomes. This study aimed to determine the optimal iodine-131 ( 131 I) intervention dose for alleviating hyperthyroidism with HI and to identify serum metabolic biomarkers for early diagnosis using UPLC-Q/TOF-MS technology. A mouse model for early 131 I intervention was established to monitor changes in physiological response, body weight, fur condition, thyroid, and liver function. Metabolite identification was achieved through UPLC-Q/TOF-MS and further analyzed via MetaboAnalyst. Six biomarkers were identified and subjected to ROC analysis. Early intervention with 80 μCi 131 I per gram of thyroid tissue effectively controlled hyperthyroidism and improved liver function. Metabolomics analysis uncovered 63 differentially abundant metabolites, six of which (L-kynurenine, Taurochenodesoxycholic acid, Glycocholic acid, Phytosphingosine, Tryptamine, and Betaine) were identified as early warning biomarkers. Post-intervention, these biomarkers progressively returned to normal levels. This study demonstrates the efficacy of UPLC-Q/TOF-MS in identifying metabolic biomarkers for early diagnosis of hyperthyroidism with HI and highlights the therapeutic potential of early 131 I intervention in normalizing these biomarkers.
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: